Tourmaline Bio (NASDAQ:TRML) vs. Tevogen Bio (NASDAQ:TVGN) Critical Analysis

Tevogen Bio (NASDAQ:TVGN) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Volatility and Risk

Tevogen Bio has a beta of -1.14, suggesting that its share price is 214% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500.

Profitability

This table compares Tevogen Bio and Tourmaline Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	-396.07%	749.97%
Tourmaline Bio	N/A	-20.97%	-20.56%

Institutional and Insider Ownership

91.9% of Tourmaline Bio shares are owned by institutional investors. 56.6% of Tevogen Bio shares are owned by company insiders. Comparatively, 11.0% of Tourmaline Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Tevogen Bio and Tourmaline Bio”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$70,000.00	N/A	N/A
Tourmaline Bio	N/A	N/A	-$42.12 million	($2.82)	-4.69

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Tevogen Bio and Tourmaline Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	0	0	1	0	3.00
Tourmaline Bio	0	0	6	0	3.00

Tevogen Bio presently has a consensus price target of $4.20, suggesting a potential upside of 153.01%. Tourmaline Bio has a consensus price target of $54.00, suggesting a potential upside of 308.16%. Given Tourmaline Bio’s higher probable upside, analysts clearly believe Tourmaline Bio is more favorable than Tevogen Bio.

Summary

Tourmaline Bio beats Tevogen Bio on 5 of the 8 factors compared between the two stocks.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

About Tourmaline Bio

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.